TargetMol

Elotuzumab (anti-SLAMF7)

Product Code:
 
TAR-T35386
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T35386-1mg1mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35386-5mg5mg£624.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma.
CAS:
0
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0

Documents

References

Regidor B, et al. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study. Ann Hematol. 2021 Apr;100(4):1079-1085. Ghai A, et al. Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1302-1311.